Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM913KS)

Drug Name
Piperazinyl methyl quinazolinone derivative 2 Drug Info
Synonyms PMID30185082-Compound-30
Cross-matching ID
PubChem CID
11214940
ChEBI ID
CHEMBL401989
CAS Number
CAS 571203-78-6
TTD Drug ID
D01IVR

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mismatch repair 2.19 0.00e+0 22/23 (95.65%) RPA3;RFC5;MSH6;...
Fanconi anemia pathway 2.15 0.00e+0 36/54 (66.67%) BRCA1;RPA3;USP1;...
Glycine, serine and threonine metabolism 2.14 0.00e+0 31/40 (77.5%) PHGDH;PSAT1;CBS;...
DNA replication 2.08 0.00e+0 34/36 (94.44%) RNASEH2A;MCM7;RPA3;...
Arginine biosynthesis 2.04 0.00e+0 17/22 (77.27%) ASS1;CPS1;GOT2;...
Cell cycle 2.03 0.00e+0 110/124 (88.71%) CDC20;PLK1;E2F2;...
One carbon pool by folate 2.01 1.02e-3 15/20 (75%) SHMT2;MTHFD2;MTHFD1;...
Butanoate metabolism 1.95 1.79e-3 23/28 (82.14%) HMGCS1;BDH1;HADH;...
Alanine, aspartate and glutamate metabolism 1.94 1.59e-3 27/37 (72.97%) ASS1;ASNS;CPS1;...
Spliceosome 1.86 2.87e-3 101/150 (67.33%) HNRNPU;SRSF7;HNRNPA3;...
Homologous recombination 1.82 6.51e-3 35/41 (85.37%) BRCA1;RPA3;BARD1;...
Valine, leucine and isoleucine degradation 1.79 7.76e-3 42/48 (87.5%) HMGCS1;ACADSB;PCCB;...
Synthesis and degradation of ketone bodies 1.73 1.43e-2 9/10 (90%) HMGCS1;BDH1;HMGCS2;...
Steroid hormone biosynthesis 1.72 1.64e-2 43/61 (70.49%) UGT2B17;UGT2B4;CYP3A5;...
Glyoxylate and dicarboxylate metabolism 1.72 1.53e-2 23/30 (76.67%) SHMT2;AGXT;PCCB;...
Cysteine and methionine metabolism 1.69 2.15e-2 43/50 (86%) PHGDH;PSAT1;CBS;...
Metabolism of xenobiotics by cytochrome P450 1.67 2.32e-2 49/77 (63.64%) AKR7A3;CBR3;GSTA1;...
Phenylalanine metabolism 1.64 3.14e-2 14/17 (82.35%) GOT2;PAH;GOT1;...
RNA transport 1.62 3.47e-2 128/186 (68.82%) EIF4EBP1;NUP85;NUP93;...
Non-homologous end-joining 1.61 3.62e-2 11/13 (84.62%) RAD50;DCLRE1C;PRKDC;...
Aminoacyl-tRNA biosynthesis 1.57 4.71e-2 15/66 (22.73%) NARS2;FARSA;DARS2;...
Caffeine metabolism 1.57 4.49e-2 5/6 (83.33%) NAT1;NAT2;CYP1A2;...
Pyruvate metabolism 1.56 4.77e-2 41/47 (87.23%) PCK2;PCK1;FH;...
Base excision repair 1.56 4.75e-2 29/33 (87.88%) PARP2;LIG3;PCNA;...
Nucleotide excision repair 1.55 4.84e-2 40/47 (85.11%) RPA3;RFC5;RFC2;...
Lipid and atherosclerosis -1.85 3.52e-3 190/215 (88.37%) AKT3;TLR2;NRAS;...
Autophagy -1.87 2.93e-3 113/169 (66.86%) MAP2K1;RAB7A;PPP2CA;...
Phagosome -1.89 2.60e-3 118/152 (77.63%) ATP6V1F;CD209;ITGB1;...
Herpes simplex virus 1 infection -1.90 1.80e-3 165/498 (33.13%) IFNA17;OAS3;HLA-DPA1;...
Glycosaminoglycan biosynthesis -1.91 1.87e-3 40/58 (68.97%) HS3ST3A1;CHST15;NDST1;...
Toxoplasmosis -1.93 1.46e-3 103/112 (91.96%) HLA-DPA1;MAPK11;BCL2;...
Rheumatoid arthritis -1.95 5.06e-4 78/93 (83.87%) ATP6V1F;ATP6V1A;FOS;...
Yersinia infection -1.97 5.28e-4 120/137 (87.59%) PTK2;CASP1;ARPC2;...
Cytokine-cytokine receptor interaction -1.97 5.52e-4 246/295 (83.39%) IL33;GH1;TNFRSF10D;...
RIG-I-like receptor signaling pathway -1.98 5.78e-4 64/70 (91.43%) ISG15;TRAF6;RNF125;...
Staphylococcus aureus infection -2.00 6.07e-4 72/95 (75.79%) HLA-DMB;HLA-DRB1;ICAM1;...
Chemokine signaling pathway -2.00 6.39e-4 163/192 (84.9%) ARRB2;ADCY8;JAK2;...
Pertussis -2.00 6.75e-4 64/76 (84.21%) C1R;IL6;IL23A;...
Legionellosis -2.00 7.14e-4 51/57 (89.47%) SAR1B;RAB1B;RAB1A;...
IL-17 signaling pathway -2.01 0.00e+0 84/94 (89.36%) TBK1;IL17RA;IKBKB;...
Tuberculosis -2.01 0.00e+0 159/180 (88.33%) RAB7A;IFNA17;HLA-DPA1;...
Leishmaniasis -2.02 0.00e+0 67/77 (87.01%) ITGB1;FOS;HLA-DPA1;...
Bacterial invasion of epithelial cells -2.06 0.00e+0 59/77 (76.62%) PTK2;ARPC2;FN1;...
Salmonella infection -2.06 0.00e+0 198/249 (79.52%) AKT3;DYNC1LI1;TLR2;...
Influenza A -2.06 0.00e+0 156/172 (90.7%) OAS2;JAK2;NXF1;...
Neutrophil extracellular trap formation -2.06 0.00e+0 101/189 (53.44%) C5AR1;AKT3;VDAC3;...
Osteoclast differentiation -2.08 0.00e+0 117/127 (92.13%) GRB2;FCGR2B;FOSB;...
Antigen processing and presentation -2.16 0.00e+0 60/78 (76.92%) PSME2;HLA-F;HLA-DPA1;...
Natural killer cell mediated cytotoxicity -2.19 0.00e+0 99/131 (75.57%) PPP3CB;KIR2DL3;NCR3;...
NOD-like receptor signaling pathway -2.20 0.00e+0 145/181 (80.11%) ATG12;MAPK10;MFN1;...
Shigellosis -2.20 0.00e+0 180/246 (73.17%) BCL2;RRAGB;DOCK1;...
TNF signaling pathway -2.25 0.00e+0 103/112 (91.96%) AKT3;ITCH;IL6;...
Chagas disease -2.26 0.00e+0 93/102 (91.18%) TRAF6;PPP2R1B;PLCB2;...
Viral protein interaction with cytokine and cytokine re... -2.28 0.00e+0 84/100 (84%) CCL13;CCL22;IL10RA;...
Toll-like receptor signaling pathway -2.42 0.00e+0 94/104 (90.38%) AKT3;TLR2;IL6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 4uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.37uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 4uM 6H
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 4uM 6H
MDST8 CVCL_1400 Homo sapiens 4uM 6H
NCI-H508 CVCL_1561 Homo sapiens 4uM 6H
SNU-1040 CVCL_5001 Homo sapiens 4uM 6H
SNU-C4 CVCL_5008 Homo sapiens 4uM 6H
SNU-C5 CVCL_5009 Homo sapiens 4uM 6H
SW480 CVCL_0546 Homo sapiens 4uM 6H
SW620 CVCL_0547 Homo sapiens 4uM 6H
SW948 CVCL_0550 Homo sapiens 4uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 4uM 6H
HT115 CVCL_1294 Homo sapiens 4uM 6H
RKO CVCL_0504 Homo sapiens 4uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 4uM 6H
SNG-M CVCL_1707 Homo sapiens 4uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 4uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 4uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 4uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 4uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 4uM 6H
T3M-10 CVCL_1729 Homo sapiens 4uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 4uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 4uM 6H
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 4uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 4uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 4uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 4uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 4uM 6H
OV7 CVCL_1623 Homo sapiens 4uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 4uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 4uM 6H
RMUG-S CVCL_1666 Homo sapiens 4uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 4uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 4uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 4uM 6H
PL-21 CVCL_2161 Homo sapiens 4uM 6H
SKM-1 CVCL_0010 Homo sapiens 4uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 4uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 4uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 4uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 4uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 4uM 6H